K. Brown

发表

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

C. Dunwiddie, R. Bentley, D. Colussi, 2001, Thrombosis research.

In vitro characterization of a novel factor Xa inhibitor, RPR 130737.

C. Dunwiddie, A. Spada, D. Colussi, 2000, Thrombosis research.

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency.

C. Dunwiddie, D. Cheney, A. Spada, 2002, Bioorganic & medicinal chemistry letters.

CN128, a new orally active hydroxypyridinone iron chelator.

Wenteng Chen, Xiaole Kong, R. Hider, 2020, Journal of medicinal chemistry.

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.

R. Bentley, D. Colussi, J. Bostwick, 2000, European journal of pharmacology.

Design of a new class of orally active fibrinogen receptor antagonists.

C. Dunwiddie, R. Bentley, J. Bostwick, 1998, Journal of medicinal chemistry.

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

C. Dunwiddie, R. Bentley, A. Spada, 1999, Journal of cardiovascular pharmacology.

Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.

A. Spada, D. Colussi, Y. Gong, 2000, Bioorganic & medicinal chemistry letters.

Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.

Robert Leadley, Guyan Liang, R. Bentley, 2003, Journal of medicinal chemistry.

Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Bioorganic & medicinal chemistry letters.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, J. Mason, 1999, Journal of medicinal chemistry.

Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors.

R. Bentley, A. Spada, C. Ly, 1999, Bioorganic & medicinal chemistry letters.

Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors.

J. Salvino, Y. M. Choi-Sledeski, Y. Gong, 2000, Bioorganic & medicinal chemistry letters.

Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.

B. Tomczuk, J. Spurlino, Tianbao Lu, 2010, Journal of medicinal chemistry.

Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Journal of medicinal chemistry.

Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.

F. Depasse, Ling He, A. Vandell, 2017, Thrombosis research.

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Daniel L Cheney, C. Dunwiddie, D. Cheney, 2002, Bioorganic & medicinal chemistry letters.